| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | BAY-41-8543 Basic information |
| Product Name: | BAY-41-8543 | | Synonyms: | BAY-41-8543;BAY-41-8543 Exclusive;BAY 41-8543
(BAY 418543);2-[1-[(2-Fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)-4,6-pyrimidinediamine;4,6-Pyrimidinediamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)-;BAY 418543,vascular,systemic,antiplatelet,vasodilator,soluble,pulmonary,orally,nitric,beds,cardiovascular,BAY 41 8543,Guanylate Cyclase,Inhibitor,sGC,BAY 41-8543,oxide,inhibit;2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5-morpholin-4-ylpyrimidine-4,6-diamine;2-(1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl)-5-morpholinopyrimidine-4,6-diamine | | CAS: | 256498-66-5 | | MF: | C21H21FN8O | | MW: | 420.44 | | EINECS: | | | Product Categories: | | | Mol File: | 256498-66-5.mol |  |
| | BAY-41-8543 Chemical Properties |
| Boiling point | 599.7±50.0 °C(Predicted) | | density | 1.55±0.1 g/cm3(Predicted) | | solubility | DMF: 3 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml | | form | A crystalline solid | | pka | 5.18±0.10(Predicted) | | color | White to off-white |
| | BAY-41-8543 Usage And Synthesis |
| Uses | BAY 41-8543, is a Guanylyl cyclase (sGC) stimulator, increasing the activity of recombinant sGC dose-dependently, from 0.1 nM to 100 μM, up to 92-fold. BAY 41-8543 reduces pulmonary vascular resistance and protects right ventricular (RV)function. It also inhibits collagen-induced platelet aggregation, and promotes lipid uptake into brown adipose tissue and increases energy expenditure in mice. It has also shown Antihypertensive activity. | | Definition | ChEBI: BAY-41-8543 is a pyrazolopyridine. | | in vivo | BAY 41-8543 (10-100 μg/kg; IV) produces small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output[1].
BAY 41-8543 (0.003, 0.01, 0.03, 0.1, and 0.3mg/kg; iv) produces a dose-dependent and long-lasting decrease in blood pressure in anaesthetized rats. The blood pressure lowering effect of BAY 41-8543 lasts longer than the observation period of 30min. BAY 41-8543 (0.1, 0.3 and 1.0mgkg; oral) has maximal blood pressure lowering effects. The blood pressure lowering effects of the highest doses of BAY41-8543 lasts longer than the observation period of 120min[2].
BAY 41-8543 (3mg/kg; p.o.; twice daily; for 5 weeks) completely prevents the development of the increase in systolic blood pressure in 18-week-old renin transgenic rats (TGR(mRen2)27) on L-NAME treatment. BAY 41-8543 dramatically increases survival[2].
| Animal Model: | Adult male Sprague-Dawley rats weighing 325-450 g[1] | | Dosage: | 10, 30, and 100 μg/kg | | Administration: | IV | | Result: | Produced small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output.
|
| | storage | Store at -20°C |
| | BAY-41-8543 Preparation Products And Raw materials |
|